Novogenia AG (ticker symbol: 7V0, formerly Darwin AG), an international healthcare company specializing in human genetics and personalized products, has announced the U.S. market launch of its new MGT Plus methylation test. The launch, conducted in collaboration with U.S. partner 10X Health, marks a significant expansion of their joint product pipeline and strengthens their international partnership in the field of innovative genetic analysis and longevity.
Methylation is a fundamental biochemical process involved in numerous metabolic and regulatory functions in the human body. As a key component of metabolic pathways, it can greatly influence the function and processing of various biological molecules, including vitamins and neurotransmitters. While commercially available tests typically analyze only a limited number of relevant genes, MGT Plus covers a total of 27 genes. This broader scope provides a more comprehensive picture of methylation processes across six interconnected biological pathways: energy and nutrient metabolism, stress and neurotransmitter regulation, and vascular, immune, and cellular health. The expanded analysis capabilities offer more precise insights into key biochemical processes, potentially leading to better-informed health decisions.
Dr. Daniel Wallerstorfer, CEO of Novogenia AG, emphasized the significance of the new test: "With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes. The significantly expanded scope of analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways in the body, creating new opportunities for more personalized prevention and health strategies. Our close collaboration with our U.S. partner 10X Health underscores our commitment to making scientific innovations accessible internationally and actively advancing personalized approaches to preventive health."
The launch comes at a time of robust growth in the global direct-to-consumer testing market. In 2025, the market size had already reached approximately $4.7 billion and is projected to grow to more than $16.0 billion by 2033. The genetic testing sector is developing particularly dynamically, with a share of over 40 percent, making it the largest segment of the market today. North America plays a leading role in this sector, accounting for around 50 percent of the global market volume in 2025. This growth is driven by increasing consumer interest in personalized health information, prevention, and individually tailored health services.
For more information about Novogenia and its offerings, visit https://novogenia.com/novogenia-ag.
